# Alipogene Tiparvovec for the Treatment of LPLD Patients

> **NCT02904772** · PHASE2 · WITHDRAWN · sponsor: **UniQure Biopharma B.V.**

## Conditions studied

- LPL Deficiency

## Interventions

- **DRUG:** alipogene tiparvovec
- **DRUG:** Prednisolone
- **DRUG:** Cyclosporins
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT02904772
- **Lead sponsor:** UniQure Biopharma B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-10
- **Primary completion:** 2020-06
- **Final completion:** 2020-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** uniQure, has decided not to renew the Marketing Authorization of Glybera in the EU. This decision is not related to any safety, efficacy or quality issue
- **Last updated:** 2017-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02904772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02904772, "Alipogene Tiparvovec for the Treatment of LPLD Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02904772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*